Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for LITS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
March 31, 2026 -1.52M
December 31, 2025 -1.929M
September 30, 2025 -4.508M
June 30, 2025 -2.461M
March 31, 2025 -3.267M
December 31, 2024 -3.666M
September 30, 2024 -11.45M
June 30, 2024 -18.21M
March 31, 2024 -2.928M
December 31, 2023 -11.06M
September 30, 2023 -18.49M
June 30, 2023 -11.30M
March 31, 2023 -12.13M
December 31, 2022 -14.27M
September 30, 2022 -14.78M
June 30, 2022 -15.50M
March 31, 2022 -16.96M
December 31, 2021 -8.566M
September 30, 2021 -7.721M
June 30, 2021 -11.26M
March 31, 2021 -15.65M
December 31, 2020 4.05M
September 30, 2020 -9.111M
June 30, 2020 69.11M
March 31, 2020 -10.30M
Date Value
December 31, 2019 -10.48M
September 30, 2019 -14.08M
June 30, 2019 -8.064M
March 31, 2019 -11.34M
December 31, 2018 2.799M
September 30, 2018 -12.82M
June 30, 2018 -3.75M
March 31, 2018 -6.239M
December 31, 2017 -4.751M
September 30, 2017 -6.562M
June 30, 2017 -3.146M
March 31, 2017 1.606M
December 31, 2016 -3.747M
September 30, 2016 8.773M
June 30, 2016 -3.483M
March 31, 2016 -4.385M
December 31, 2015 -4.228M
September 30, 2015 -5.761M
June 30, 2015 -6.742M
March 31, 2015 -8.148M
December 31, 2014 -6.448M
September 30, 2014 -6.731M
June 30, 2014 -5.85M
March 31, 2014 -5.071M
December 31, 2013 -4.467M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. -7.588M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M
Savara, Inc. -29.75M